Sugi Predict

Sugi Predict / Compounds / SCHEMBL852844

SCHEMBL852844

SCHEMBL852844

COc1cccc(C#C[Si](C)(C)C)c1

nearest known ligand 0.59

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 5/20 0.59
▸ CA12 O43570 2/20 0.51
▸ CA1 P00915 2/20 0.51
▸ CA2 P00918 2/20 0.51
▸ CA9 Q16790 2/20 0.51
▸ CHRM2 P08172 1/20 0.47
▸ CHRM1 P11229 1/20 0.47
▸ CHRM3 P20309 1/20 0.47
▸ FFAR1 O14842 1/20 0.46
▸ ACHE P22303 1/20 0.44
▸ HAO1 Q9UJM8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6132140 0.84 GRM5 (0.66) GRM5CA12CA1CA2CA9
SCHEMBL30707880 0.84 GRM5 (0.66) GRM5CA12CA1CA2CA9
SCHEMBL3614755 0.82 GRM5 (0.39) GRM5
SCHEMBL673173 0.80 ALDH1A1 (0.48) GRM5
SCHEMBL22616848 0.80 NQO1 (0.47) GRM5CA12CA1CA2CA9
SCHEMBL1476032 0.80 GRM5 (0.56) GRM5CHRM2CHRM1CHRM3FFAR1
SCHEMBL29994376 0.79 GRM5 (0.56) GRM5CA12CA1CA2CA9
SCHEMBL28215433 0.79 GRM5 (0.56) GRM5CA12CA1CA2CA9
SCHEMBL7601866 0.79 GRM5 (0.56) GRM5CA12CA1CA2CA9
SCHEMBL4267103 0.79 CA12 (0.63) GRM5CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814462-B2 Functionalized cyclic polymers and methods of preparing same UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2023-11-14 — — US claimed
US-20220056167-A1 Functionalized Cyclic Polymers and Methods of Preparing Same NATIONAL SCIENCE FOUNDATION 2022-02-24 — — US claimed
WO-2020223672-A1 FUNCTIONALIZED CYCLIC POLYMERS AND METHODS OF PREPARING SAME UNIVERSITY OF FLORIDA RESEARCHFOUNDATION, INC. (US) 2020-11-05 — — WO claimed
US-11814462-B2 Functionalized cyclic polymers and methods of preparing same UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2023-11-14 — — US disclosed
US-20230018615-A1 STEROIDS AND METHODS OF MANUFACTURE TRUSTEES OF DARTMOUTH COLLEGE 2023-01-19 — — US disclosed
US-20220056167-A1 Functionalized Cyclic Polymers and Methods of Preparing Same NATIONAL SCIENCE FOUNDATION 2022-02-24 — — US disclosed
WO-2020223672-A1 FUNCTIONALIZED CYCLIC POLYMERS AND METHODS OF PREPARING SAME UNIVERSITY OF FLORIDA RESEARCHFOUNDATION, INC. (US) 2020-11-05 — — WO disclosed
WO-2019144845-A1 SPIRO-CONTAINING PLATINUM (II) EMITTERS WITH TUNABLE EMISSION ENERGIES AND SYNTHESES THEREOF THE UNIVERSITY OF HONG KONG (CN) 2019-08-01 — — WO disclosed
US-8859581-B2 Azaheterocyclic compounds as kinase inhibitors MERCK PATENT GMBH (DE) 2014-10-14 — — US disclosed
EP-1425010-B8 SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS JANSSEN PHARMACEUTICALS INC (US) 2012-03-28 — — EP disclosed
EP-1425010-B1 SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS ORTHO MCNEIL PHARM INC (US) 2011-10-26 — — EP disclosed
US-20030096846-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method CHENG PETER T (US) 2003-05-22 — — US disclosed
US-20030087935-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method CHENG PETER T (US) 2003-05-08 — — US disclosed
US-20030069275-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method CHENG PETER T (US) 2003-04-10 — — US disclosed
US-20020169200-A1 Substituted indoles and their use as integrin antagonists 3-DIMENSIONAL PHARMACEUTICALS, INC. 2002-11-14 — — US disclosed
WO-2002060438-A1 SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2002-08-08 — — WO disclosed
EP-1218361-A1 OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-07-03 — — EP disclosed
US-6414002-B1 ANTILIPEMIC AGENTS; ANTICANCER, ANTITUMOR AGENTS BRISTOL-MYERS SQUIBB COMPANY 2002-07-02 — — US disclosed
WO-2001021602-A1 OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-03-29 — — WO disclosed
WO-2000024742-A1 PYRAZOLOPYRIDINE AS ADENOSINE ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069275-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method GPR119, LIPC, PNLIP GRM5 1422/4885CA12 2693/4885CA1 2579/4885
US-20230018615-A1 STEROIDS AND METHODS OF MANUFACTURE HSD17B7, HSD11B1, HSD11B2 GRM5 3181/4885CA12 2347/4885CA1 2634/4885
US-20030096846-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method GPR119, LIPC, PNLIP GRM5 1422/4885CA12 2693/4885CA1 2579/4885
US-20030087935-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method GPR119, LIPC, PNLIP GRM5 1422/4885CA12 2693/4885CA1 2579/4885
US-20020169200-A1 Substituted indoles and their use as integrin antagonists ITGAV, ITGAL, ITGA5 GRM5 554/4885CA12 4396/4885CA1 4003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.